97037 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants; Immunoglobulin superfamily B7 molecules, e.g. CD80, CD86
COLLAGEN-LOCALIZED IMMUNOMODULATORY MOLECULES AND METHODS THEREOF
#2PLATFORMS, COMPOSITIONS, AND METHODS FOR THERAPEUTIC DELIVERY
#3Bispecific Tetravalent Antibodies and Methods of Making and Using Thereof
#4NOVEL COMPOSITION COMPRISING ANTIBODIES
#5PD-L1 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#6COMBINATION THERAPY OF ONCOLYTIC VIRUS DRUGS FOR CANCER TREATMENT
#7ENHANCED FUSION POLYPEPTIDE FOR IMMUNOTHERAPY
#8PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE
#9LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY
#10LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY
#11COMPOSITIONS AND METHODS OF CHIMERIC ALLOANTIGEN RECEPTOR T CELLS
#12COMBINATION THERAPY FOR LUNG CANCER
#13Methods For Reducing Or Preventing Cerebral Edema After Stroke
#14ANTI-CD7 NANOBODY, AND DERIVATIVE THEREOF AND USE THEREOF IN TUMOR THERAPY
#15CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#16Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related Thereto
#17CLAUDIN18.2 HUMANIZED ANTIBODY AND APPLICATION THEREOF
#18NUCLEOTIDE DELIVERY OF CANCER THERAPY
#19METHODS TO GENERATE ENHANCED TUMOR INFILTRATING LYMPHOCYTES THROUGH MICROFLUIDIC DELIVERY
#20ICOS-L VARIANT WITH ENHANCED BINDING AFFINITY FOR ICOS
#21CHIMERIC, TRANSMEMBRANE PROTEINS WITH BIDIRECTIONAL SIGNALLING ACTIVITY
#22THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#23ONE-STEP CONSTRUCTION OF ALLOGENIC CAR-NK CELLS WITH INCREASED ANTI-TUMOR CYTOTOXICITY AND RESISTANCE TO HOST CELL REJECTION
#24COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#25EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#26PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE
#27ENHANCED ANTIGEN PRESENTING ABILITY OF CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULES
#28MULTIVALENT DISPLAY ON ENVELOPED PARTICLES WITH HUMAN OLIGOMERIZATION DOMAINS
#29LYMPHOCYTE TARGETED LENTIVIRAL VECTORS
#30METHODS AND MATERIALS FOR TREATING GRAFT-VERSUS-HOST DISEASE
#31IMMUNOMODULATORY PROTEINS OF VARIANT CD80 POLYPEPTIDES, CELL THERAPIES AND RELATED METHODS AND USES
#32PDL2 COMPOUNDS
#33NATURAL KILLER CELLS EXPRESSING DUAL-TARGETING CHIMERIC ANTIGEN RECEPTORS FOR CD19 AND CD22, PRODUCTION METHOD AND USES THEREOF
#34A FUSION POLYPEPTIDE AND ITS USE
#35FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF
#36PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGENBINDING PROTEINS
#37COMPOSITIONS AND METHODS FOR TREATING A REFRACTORY OR RELAPSED CANCER OR A CHRONIC INFECTIOUS DISEASE
#38CD80 PROTEIN VARIANT AND CD80 FUSION PROTEIN
#39TGF-Beta Polypeptides
#40ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents
#41COMPOSITIONS AND METHODS FOR TREATMENT OF SJÖGREN'S SYNDROME AND/OR SYSTEMIC LUPUS ERYTHEMATOSUS
#42DUAL CHECKPOINT INHIBITORS AND METHODS OF USING THE SAME
#43MULTI-DOMAIN IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
#44ARTIFICIAL SYNAPSES
#45LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY
#46ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION
#47NOVEL IMMUNOSTIMULATING VECTOR SYSTEM
#48VIRAL VECTORS AND PACKAGING CELL LINES
#49VIRAL VECTORS AND PACKAGING CELL LINES
#50CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#51Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein
#52VIRAL PARTICLE WITH SURFACE STIMULATING MOLECULES
#53POLYPEPTIDE MODULATORS
#54METHODS TO GENERATE ENHANCED TUMOR INFILTRATING LYMPHOCYTES THROUGH MICROFLUIDIC DELIVERY
#55NON-CYTOTOXIC MODIFIED CELLS AND USE THEREOF
#56MULTICISTRONIC CHIMERIC PROTEIN EXPRESSION SYSTEMS
#57Immune Cell Binding Polypeptides
#58TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME
#59Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#60INHIBITORS OF T-CELL ACTIVATION
#61ICOS LIGAND VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#62E PROTEIN-MUTATED WEST NILE VIRUS USED AS LIVEATTENUATED VACCINE AND ONCOLYTIC DRUG FOR CANCER THERAPY
#63NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME
#64PD-1 AGONIST
#65COMPOSITIONS AND METHODS COMPRISING CAR T CELLS COMPRISING PRDM1 AND/OR NR4A3 KNOCKOUT
#66MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
#67HYPOIMMUNE CELLS
#68ATP-dependent agonists of immune cells function as anticancer agents
#69CHIMERIC POLYPEPTIDES AND METHODS OF USE
#70FUSION PROTEINS OF PD-1 AND 4-1BB
#71SYNTHETIC PROTEIN FOR INDUCING IMMUNE TOLERANCE
#72Ligand discovery and gene delivery via retroviral surface display
#73CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN THERAPY
#74LYMPHOCYTE TARGETED LENTIVIRAL VECTORS
#75CHIMERIC ANTIGEN RECEPTORS TO SIALYL-TN GLYCAN ANTIGEN
#76CHIMERIC POLYPEPTIDES, NUCLEIC ACID MOLECULES, CELLS, AND RELATED METHODS
#77FUSION PROTEINS AND USES THEREOF
#78HUMANIZED ANTI-SIALYL-TN GLYCAN ANTIBODIES AND USES THEREOF
#79ANTIGEN RECOGNIZING RECEPTORS TARGETING CD33 AND USES THEREOF
#80Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
#81Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof
#82HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE
#83REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES FOR USE IN DETERMINING PRESENCE AND OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES
#84Lymphocyte targeted lentiviral vectors
#85PROTEIN FUSED WITH MOLECULE CAPABLE OF BINDING TO IMMUNE CHECKPOINT MOLECULE AND USE OF SAME
#86METHODS AND COMPOSITIONS FOR CELLULAR THERAPY
#87IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
#88NOVEL BICYCLIC PEPTIDES
#89COMBINATION THERAPY OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS
#90ENGINEERED CELLS FUNCTIONALIZED WITH IMMUNE CHECKPOINT MOLECULES AND USES THEREOF
#91BIFUNCTIONAL PROTEIN AND USE THEREOF
#92CHIMERIC TIM4 RECEPTORS AND USES THEREOF
#93MODIFIED IMMUNE EFFECTOR CELL AND USE THEREOF
#94Ligand discovery and gene delivery via retroviral surface display
#95CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT
#96Antibody Immune Cell Inhibitor Fusion Proteins
#97Expression System for Protein Production and Screening
#98EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY
#99Oncolytic virus vector and application thereof
#100THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND USES THEREOF
#101CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#102INTESTINAL EXPRESSION OF PROGRAMMED DEATH LIGAND 1
#103TGF-Beta Polypeptides
#104Allograft tolerance without the need for systemic immune suppression
#105VISTA AGONIST FOR TREATMENT/PREVENTION OF ISCHEMIC AND/OR REPERFUSION INJURY
#106CHIMERIC ANTIGEN COMPRISING THE EXTRACELLULAR DOMAIN OF PD-L1
#107CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN REGIMENS
#108AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMUNOTHERAPY OF CANCER
#109CD155 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#110EXTRACELLULAR VESICLES WITH IMMUNE MODULATORS
#111DOWNREGULATION OF MEMBRANE-BOUND PROTEINS BY RECEPTOR TAC TECHNOLOGY
#112Proinsulin Peptides for Type I Diabetes
#113MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#114MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
#115SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES
#116RECOMBINANT POXVIRIDAE VECTOR EXPRESSING CO-STIMULATORY MOLECULES
#117UNIVERSAL DONOR CELLS
#118Protein Tyrosine Phosphatase 1B Inhibited Neutrophils, Neutrophil-Dendritic Cell Hybrids and Uses Thereof
#119CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATING AUTOIMMUNITY
#120MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
#121PD-L1 EXPRESSING HEMATOPOIETIC STEM CELLS AND USES
#122ARTIFICIAL SYNAPSES
#123T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#124PD1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AS AN IMMUNOTHERAPY
#125Exosome for stimulating T cell and pharmaceutical use thereof
#126NKP30 BINDERS
#127T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#128STEALTH CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF IN REDUCING CYTOTOXICITY TOWARDS NORMAL CELLS
#129UNIVERSAL DONOR CELLS
#130MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#131VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS
#132FC-CD80 FUSION PROTEIN AND CONJUGATES THEREOF AND THEIR USES
#133PHARMACEUTICAL COMPOSITION FOR ENHANCING RADIOTHERAPY COMPRISING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN
#134T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#135PDL2 compounds
#136CHIMERIC ANTIGEN RECEPTOR FOR TREATMENT OF CANCER
#137ANTIBODIES SPECIFIC FOR CD22 AND USES THEREOF
#138ENHANCED EXPRESSION SYSTEM AND METHODS OF USE THEREOF
#139ANTI-PD-L1 ANTIBODIES
#140UNIVERSAL DONOR CELLS
#141UNIVERSAL DONOR CELLS
#142UNIVERSAL DONOR CELLS
#143Screening method for effective target - E3 ligase combinations
#144Collagen-localized immunomodulatory molecules and methods thereof
#145PD-L1 BINDING PEPTIDES
#146GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD276
#147ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF
#148FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN FRAGMENT OR VARIANT THEREOF, AND USES THEREOF
#149CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#150Recombinant PD-L1 peptides and methods of use
#151Fusion Protein Extensions
#152UNIVERSAL DONOR CELLS
#153FUSION PROTEIN COMPRISING PD-L1 PROTEIN AND USE THEREOF
#154METHODS OF MAKING TOLEROGENIC DENDRITIC CELLS
#155FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF
#156Multi-domain immunomodulatory proteins and methods of use thereof
#157UNIVERSAL DONOR CELLS
#158NK CELL-DIRECTED CHIMERIC PROTEINS
#159PERICYTE-SPARING THERAPY
#160CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN REGIMENS
#161CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#162PD-1 VARIANT HAVING IMPROVED BINDING ABILITY TO PD-L1
#163Chimeric antigen receptors, compositions and applications thereof
#164THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#165ARTIFICIAL SYNAPSES
#166Compositions and Methods for Treating Cancer with Anti-ROR1 Immunotherapy
#167Platforms, compositions, and methods for therapeutic delivery
#168Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
#169IMMORTALIZED CARDIAC STEM CELLS FOR CARDIAC REPAIR
#170Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
#171FUSION PROTEINS OF PD-1 AND 4-1BB
#172CD86 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#173TGF-β polypeptides
#174CHIMERIC ANTIGEN RECEPTOR COMPRISING ANTI C-MET ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, AND USE THEREOF
#175COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
#176BIOASSAY FOR T-CELL CO-STIMULATORY PROTEINS CONTAINING FC DOMAINS
#177METHODS OF B CELL EXPANSION FOR USE IN CELL THERAPY
#178MULTIMERIC PROTEIN DOMAINS FOR MULTIFUNCTIONALITY AND ENHANCED SECRETION OF THERAPEUTIC PROTEINS
#179Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion
#180Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion
#181CHIMERIC PROTEINS IN AUTOIMMUNITY
#182FUSION PROTEIN TARGETING PD-L1 AND TGF-ß AND USE THEREOF
#183NOVEL COMPOSITION COMPRISING ANTIBODIES
#184RECOMBINANT ONCOLYTIC VIRUS, SYNTHETIC DNA SEQUENCE, AND APPLICATION THEREOF
#185CELL-TYPE SELECTIVE IMMUNOPROTECTION OF CELLS
#186METHOD FOR PRODUCING CELL POPULATION CONTAINING CAR-EXPRESSING IMMUNE CELLS
#187COMPOSITIONS AND METHODS FOR TREATING CEREBRAL VASOSPASM
#188EXTRACELLULAR VESICLES TARGETING T CELLS AND USES THEREOF
#189ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME
#190IMMUNOMODULATORY PROTEINS WITH TUNABLE AFFINITIES
#191IMMUNE CELL RECEPTORS COMPRISING CD4 BINDING MOIETIES
#192DENDRITIC CELL-BASED CANCER VACCINES AND PREPARATION METHOD THEREOF
#193PHARMACEUTICAL FORMULATIONS CONTAINING CD80 EXTRACELLULAR DOMAIN-FC FUSION PROTEINS
#194CD80 VARIANT PROTEINS AND USES THEREOF
#195COMPOSITIONS AND METHODS OF CHIMERIC ALLOANTIGEN RECEPTOR T CELLS
#196Universal donor cells
#197Universal donor cells
#198COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS
#199METHODS AND USES OF VARIANT CD80 FUSION PROTEINS AND RELATED CONSTRUCTS
#200Chimeric antigen receptors (CARS) that bind osteosarcoma and their use in medicine
#201CD80 variant immunomodulatory proteins and uses thereof
#202HUMAN VACCINE COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA
#203CD80 variant immunomodulatory proteins and uses thereof
#204ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING A MEMBER OF THE B7 FAMILY OF COSTIMULATORY LIGANDS AND ADA
#205Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof
#206FUSION POLYPEPTIDE FOR IMMUNOTHERAPY
#207Variant ICOS ligand immunomodulatory proteins and related compositions and methods
#208MULTICELL CONJUGATES FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES
#209MULTI-TARGETING FUSION PROTEIN FOR BLOCKING THE GROWTH OF VASCULAR ENDOTHELIAL CELLS AND ACTIVATING T CELLS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
#210T-CELL MODULATORY ANTIGEN-PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF
#211mRNA combination therapy for the treatment of cancer
#212FUSION PROTEIN WITH IMMUNOSUPPRESSIVE ACTIVITY
#213RECOMBINANT HUMAN 2IG-B7-H3 PROTEIN CODING GENE, RECOMBINANT VECTOR, HOST CELL COMPRISING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
#214ENGINEERED ONCOLYTIC VIRUSES EXPRESSING PD-L1 INHIBITORS AND USES THEREOF
#215UNIVERSAL DONOR CELLS
#216Multifunctional protein
#217Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related Thereto
#218VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER
#219MUTANT VARIANTS OF PD-1 RECEPTOR WITH SELECTIVE BINDING TO PD-L1 AND USES THEREOF
#220TARGETED IMMUNOTOLERANCE
#221CANCER-STEM-CELL-SPECIFIC ANTIBODY
#222MULTICISTRONIC VECTOR FOR SURFACE ENGINEERING LENTIVIRAL PARTICLES
#223IMMUNOMODULATORY CELLS AND USES THEREOF
#224COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#225ANTI-PD-1 VACCINE COMPOSITION
#226Subcutaneous Delivery of Adenovirus with Dual Targeting
#227Inhibitors of T-cell activation
#228Extracellular vesicles comprising engineered fusion proteins
#229Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein
#230Artificial synapses
#231Universal donor cells
#232BIFUNCTIONAL BINDING POLYPEPTIDES
#233PD-L1 PRESENTING PLATELETS REVERSE NEW-ONSET TYPE 1 DIABETES
#234Universal donor cells
#235METHODS FOR PROMOTING PANCREATIC ISLET CELL GROWTH
#236CD80 variant immunomodulatory proteins and uses thereof
#237Composition for Preventing or Treating Immune-Related Diseases
#238CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN DOSING REGIMENS
#239Compositions and methods for enhancing the stability of transgenes in poxviruses
#240ONCOLYTIC ADENOVIRUS ENCODING A B7 PROTEIN
#241Oncolytic Vaccinia Virus With Modified B5R Gene For The Treatment Of Cancer
#242METHOD FOR PROVIDING INFORMATION ON THERAPEUTIC REACTION OF CANCER IMMUNOTHERAPY AND KIT USING SAME
#243PD-L1 variants with enhanced binding affinity to PD-1
#244Enhanced antigen presenting ability of RNA car T cells by co-introduction of costimulatory molecules
#245Anti-EGFR1-PD1 targeted/immunomodulatory fusion protein
#246Bispecific Tetravalent Antibodies and Methods of Making and Using Thereof
#247TARGETED IMMUNOTOLERANCE
#248PD-1 and CTLA-4 Dual Inhibitor Peptides
#249TWEAK-receptor agonists for use in combination with immunotherapy of a cancer
#250Antibody immune cell inhibitor fusion proteins
#251Immunostimulating vector system
#252ICOSL for use as a Renal Therapeutic
#253Multimodal Vector for Dendritic Cell Infection
#254ICOS ligand variant immunomodulatory proteins and uses thereof
#255CD80 variant immunomodulatory proteins and uses thereof
#256NUCLEIC ACID APTAMERS
#257UNIVERSAL DONOR STEM CELLS AND RELATED METHODS
#258CD80 variant immunomodulatory proteins and uses thereof
#259CD80 variant immunomodulatory proteins and uses thereof
#260ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION
#261CD80 variant immunomodulatory proteins and uses thereof
#262CD80 variant immunomodulatory proteins and uses thereof
#263MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
#264Viral vectors and packaging cell lines
#265VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#266METHODS AND MATERIALS FOR TREATING GRAFT-VERSUS-HOST DISEASE
#267Method for the treatment of malignancies
#268CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR OR ENGINEERED TCR AND COMPRISING A NUCLEOTIDE SEQUENCE WHICH IS SELECTIVELY EXPRESSED
#269PD-L2 variant immunomodulatory proteins and uses thereof
#270CD80 variant immunomodulatory proteins and uses thereof
#271Universal donor cells
#272System and products for improved quantification of ADCC and ADCP activity
#273Universal donor cells
#274Universal donor cells
#275Universal donor cells
#276Compounds useful as immunomodulators
#277High affinity PD-1 agents and methods of use
#278B7-H4 antibodies and methods of use thereof
#279Guidance and Navigation Control proteins and method of making and using thereof
#280METHODS OF MAKING AND USING GUIDANCE AND NAVIGATION CONTROL PROTEINS
#281VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES
#282METHODS FOR PROMOTING PANCREATIC ISLET CELL GROWTH
#283Exosomes for immuno-oncology and anti-inflammatory therapy
#284NK CELL-DIRECTED CHIMERIC PROTEINS
#285PDL2 compounds
#286Ligand discovery and gene delivery via retroviral surface display
#287BSL2v2c2-Ig POLYPEPTIDES
#288METHODS AND COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR TARGETING CANCER CELLS
#289Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
#290Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
#291Universal donor cells
#292Universal donor cells
#293Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
#294Peptides for molecular detection of PD-L1
#295Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1
#296VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS
#297Chimeric endocytic receptors and method of use thereof
#298PD1-specific chimeric antigen receptor as an immunotherapy
#299Anti-PD-L1 antibodies and diagnostic uses thereof
#300B7-H5, a costimulatory polypeptide